2024-02-22 18:56:04 ET
Provectus Biopharmaceuticals, Inc. (PVCT)
Q1 2024 Earnings Conference Call
February 22, 2024 3:00 PM ET
Company Participants
Alyssa Barry – irLabs Investor Relations
Nathan Kibler – Outside Legal Counsel-Baker Donelson
Ed Pershing – Chairman
Dominic Rodrigues – Board Vice Chairman
Conference Call Participants
Presentation
Operator
Thank you for standing by. This is the conference operator. Welcome to the Provectus Biopharmaceuticals First Quarter 2024 Conference Call. As a reminder, all participants are in listen-only mode and the conference is being recorded.
I would now like to turn the conference over to Alyssa Barry, irLabs Investor Relations. Please go ahead.
Alyssa Barry
Thank you, operator. Good afternoon. Welcome to the first quarter 2024 conference call of Provectus Biopharmaceuticals, which is developing immunotherapy medicines for cancer and other diseases. My name is Alyssa Barry, Co-Founder and Principal of investor relations firm irLabs. I am hosting today’s call. Ed Pershing, Chairman of Provectus’ Board of Directors, and Dominic Rodrigues, Board Vice Chairman, will provide company updates and their remarks.
First, Nathan Kibler, Provectus’ Outside Legal Counsel from the law firm of Baker Donelson, will read the company’s forward-looking statements....
Read the full article on Seeking Alpha
For further details see:
Provectus Biopharmaceuticals, Inc. (PVCT) Q1 2024 Earnings Call Transcript